Acadia Pharmaceuticals Inc
ACAD· Nasdaq
ACADAcadia Pharmaceuticals Inc
Released Feb 26, 2025, after the close
10-K filed Feb 27, 2025, 58 days after period end · 0000950170-25-029253
derived · Computed from the longer spans the company filed.
| Metric | Q4 2024dderived from reported figures | Q4 2023 | Q4 2022 | Q4 2021 |
|---|---|---|---|---|
| Revenue | $259.60M | $231.04M | $136.49M | $130.76M |
| Net Income | $143.74M | $45.80M | -$41.73M | -$43.09M |
Acadia Pharmaceuticals Inc · CIK 1070494 · Engraved from SEC EDGAR
| EPS Diluted | — | $0.28 | -$0.26 | -$0.27 |
|---|
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
